{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Large Context with Legal Documents Demo\n",
    "\n",
    "## Install Libraries\n",
    "\n",
    "```\n",
    "pip install jupyter pypdf validators\n",
    "```\n",
    "\n",
    "Optionally you can install tika, which requires Java installed. Tika reads pdf files as alternative to pypdf.\n",
    "```\n",
    "pip install tika\n",
    "```"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import uuid\n",
    "from pprint import pprint\n",
    "from ai21 import AI21Client\n",
    "from ai21.models.chat import ChatMessage, DocumentSchema\n",
    "\n",
    "ai21_api_key = (os.environ.get(\"AI21_API_KEY\"))\n",
    "\n",
    "if not ai21_api_key:\n",
    "    raise ValueError(\"Please set the environment variable AI21_API_KEY\")\n",
    "\n",
    "client = AI21Client(\n",
    "    # This is the default and can be omitted\n",
    "    api_key=ai21_api_key,\n",
    ")\n",
    "\n",
    "# list all files in a directory\n",
    "def list_files(directory, extension=None):\n",
    "    if extension:\n",
    "        return [f for f in os.listdir(directory) if os.path.isfile(os.path.join(directory, f)) and f.endswith(extension)]\n",
    "    else:\n",
    "        return [f for f in os.listdir(directory) if os.path.isfile(os.path.join(directory, f))]\n",
    "\n",
    "# read pdf file and extract text\n",
    "def read_pdf_file(file_name, preprocess=False, package=\"pypdf\"):\n",
    "    \n",
    "    if package == \"pypdf\":\n",
    "        return read_pdf_file_with_pypdf(file_name, preprocess)\n",
    "    elif package == \"tika\":\n",
    "        return read_pdf_file_with_tika(file_name, preprocess)\n",
    "    else:\n",
    "        raise ValueError(f\"Package {package} not supported\")\n",
    "    \n",
    "\n",
    "def read_pdf_file_with_pypdf(file_name, preprocess=False):\n",
    "    from pypdf import PdfReader\n",
    "    \n",
    "    with open(file_name, 'rb') as f:\n",
    "        reader = PdfReader(f)\n",
    "\n",
    "        pypdf_content = \"\"\n",
    "        for page in reader.pages:\n",
    "            current_page = page.extract_text()\n",
    "            pypdf_content += '\\n\\n' + current_page\n",
    "\n",
    "        if preprocess:\n",
    "            pypdf_content = re.sub(r'\\s+', ' ', pypdf_content)\n",
    "\n",
    "        return pypdf_content\n",
    "\n",
    "\n",
    "def read_pdf_file_with_tika(file_name, preprocess=False):\n",
    "    from tika import parser\n",
    "    import re\n",
    "\n",
    "    parsed_pdf = parser.from_file(file_name)\n",
    "    tika_content = parsed_pdf['content']\n",
    "\n",
    "    if preprocess:\n",
    "        # remove extra spaces\n",
    "        tika_content = re.sub(r'\\s+', ' ', tika_content)\n",
    "\n",
    "    return tika_content"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## PDF Files"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['../data/pdfs/PDF Document4.pdf', '../data/pdfs/PDF Document3.pdf', '../data/pdfs/PDF Document2.pdf', '../data/pdfs/PDF Document.pdf']\n"
     ]
    }
   ],
   "source": [
    "PDF_FILE_HOME = \"../data/pdfs/\"\n",
    "PDF_FILES = [os.path.join(PDF_FILE_HOME, f) for f in list_files(PDF_FILE_HOME, \"pdf\")]\n",
    "\n",
    "print(PDF_FILES)\n",
    "\n",
    "pdf1_doc = read_pdf_file(PDF_FILES[3])\n",
    "assert \"DEPARTMENT OF THE TREASURY\" in pdf1_doc[:100]\n",
    "assert \"Notice of proposed rulemaking and request for public comment.\" in pdf1_doc[:1000]\n",
    "pdf1_doc = DocumentSchema(\n",
    "    id=str(uuid.uuid4()),\n",
    "    content=pdf1_doc,\n",
    ")\n",
    "\n",
    "pdf2_doc = read_pdf_file(PDF_FILES[2])\n",
    "assert \"KAR AUCTION SERVICES, INC.\" in pdf2_doc[:1000]\n",
    "assert \"CARVANA GROUP, LLC\" in pdf2_doc[:1000]\n",
    "pdf2_doc = DocumentSchema(\n",
    "    id=str(uuid.uuid4()),\n",
    "    content=pdf2_doc,\n",
    ")\n",
    "\n",
    "pdf3_doc = read_pdf_file(PDF_FILES[1])\n",
    "assert \"THOMAS HIGH PERFORMANCE GREEN FUND\" in pdf3_doc[:10000]\n",
    "pdf3_doc = DocumentSchema(\n",
    "    id=str(uuid.uuid4()),\n",
    "    content=pdf3_doc,\n",
    ")\n",
    "\n",
    "pdf4_doc = read_pdf_file(PDF_FILES[0])\n",
    "assert \"AAVANTIBIO\" in pdf4_doc[:1000]\n",
    "pdf4_doc = DocumentSchema(\n",
    "    id=str(uuid.uuid4()),\n",
    "    content=pdf4_doc,\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "\n",
    "## Document Prompts\n",
    "\n",
    "### PDF1 Use Case"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "initial_prompt1 = ChatMessage(\n",
    "    role='user',\n",
    "    content='''\n",
    "    You are an M&A partner at a top global law firm. You should showcase expertise and capabilities when answering questions, and at the same time the answers should be digestible, similar in tone to conversation at a business lunch, and avoid using jargon.\n",
    "    \n",
    "    Draft a client alert (a three page write up that will be published online and sent to existing and potential clients to highlight my knowledge, insight, and expertise) about the proposed rule attached. The Proposed Rule revives a proposal first made in 2016 regarding rules on incentive-based compensation arrangements at certain financial institutions with at least $1 billion in assets, but newly includes a preamble that proposes certain alternatives and questions that will be considered for the final rule. The information in this preamble, which is under the heading of \"Overview of the 2024 Proposed Rule\" and the questions that will be considered for the final rule are very important to address in my client memo and should be discussed in the most detail. \n",
    "\n",
    "    Please draft this three page client alert, making sure to include the key provisions of the proposed rule, a summary and analysis of the preamble and questions that will be considered, and potential impact to larger financial institutions regarding executive compensation arrangements. While the client alert should showcase my expertise and my firm's capabilities, it should be digestible, similar in tone to conversation at a business lunch, and not use jargon.\n",
    "    '''\n",
    ")\n",
    "system_prompt1 = ChatMessage(\n",
    "        role='system_prompt',\n",
    "        content=''' \n",
    "Draft a client alert about the proposed rule and request for public comment in the document. Client alert is a three page write up that will be published online and sent to existing and potential clients to highlight my knowledge, insight, and expertise. \n",
    "The Proposed Rule revives a proposal first made in 2016 regarding rules on incentive-based compensation arrangements at certain financial institutions with at least $1 billion in assets.\n",
    "\n",
    "IMPORTANT: \n",
    "  * The Proposed Rule contains a preamble under the heading of \"Overview of the 2024 Proposed Rule\" that proposes certain alternatives and questions that will be considered for the final rule. \n",
    "  * The information in this preamble under the heading of \"Overview of the 2024 Proposed Rule\" and the questions that will be considered for the final rule are very important to address in this client memo. \n",
    "  * The information in the preamble under the heading of \"Overview of the 2024 Proposed Rule\" should be discussed in the most detail. \n",
    "  * The draft should provide as much detail as possible, include and explain all facts and conclusions derived from the document, and present all supporting information and analysis\n",
    "  * Use bullet points where appropriate. \n",
    "  * While the answer should showcase the expertise and firm's capabilities, it should be digestible, similar in tone to conversation at a business lunch, and not use jargon.\n",
    "    '''\n",
    ")\n",
    "client_prompts1 = [\n",
    "    ChatMessage(\n",
    "        role='user',\n",
    "        content='''\n",
    "        What are the key provisions of the proposed rule? Provide as much detail and context as possible. Be extremely detail oriented, verbose, and include all supporting information and analysis.\n",
    " \n",
    "        '''\n",
    "    ),\n",
    "    ChatMessage(\n",
    "        role='user',\n",
    "        content=''' \n",
    "        Write a summary and analysis of the preamble and questions that will be considered. Provide as much detail and context as possible. Be extremely detail oriented, verbose, and include all supporting information and analysis.\n",
    "        '''\n",
    "    ),\n",
    "    ChatMessage(\n",
    "        role='user',\n",
    "        content='''\n",
    "        What is the potential impact to larger financial institutions regarding executive compensation arrangements? Provide as much detail and context as possible. Be extremely detail oriented, verbose, and include all supporting information and analysis.\n",
    "        '''\n",
    "    ),\n",
    "    ChatMessage(\n",
    "        role='user',\n",
    "        content=''' \n",
    "        Draft three page client alert, based on the last 3 answers, making sure to include the key provisions of the proposed rule, a summary and analysis of the preamble and questions that will be considered, and potential impact to larger financial institutions regarding executive compensation arrangements. Provide as much detail and context as possible. Be extremely detail oriented, verbose, and include all supporting information and analysis.\n",
    "        '''\n",
    "    ),\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### PDF2 Use Case"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "initial_prompt2 = ChatMessage(\n",
    "    role='user',\n",
    "    content = '''\n",
    "    What's a no-shop provision? How often are they included in private acquisition agreements? Does the agreement attached contain a no-shop and if so, what section is it?\n",
    "    '''\n",
    ")\n",
    "system_prompt2 = ChatMessage(\n",
    "    role='system',\n",
    "    content = '''\n",
    "    You are an expert in securities and asset management law. Please provide a detailed explanation of each question in the document.  \n",
    "    The document is a SECURITIES AND ASSET PURCHASE AGREEMENT.\n",
    "    \n",
    "    Important directions when answering the questions:\n",
    "     * The answers should contain as much detail as possible.\n",
    "     * Include and explain all facts and conclusions derived from the document\n",
    "     * Present all supporting information and analysis\n",
    "     * Provide all references from the document including article number, section number, and title. \n",
    "    '''\n",
    ")\n",
    "client_prompts2 = [\n",
    "    ChatMessage( \n",
    "        role='user',\n",
    "        content = \"What's a no-shop provision? \"\n",
    "    ),\n",
    "    ChatMessage(\n",
    "        role='user', \n",
    "        content=\"How often are they included in private acquisition agreements?\"\n",
    "    ),\n",
    "    ChatMessage(\n",
    "        role='user',\n",
    "        content=\"Does the agreement attached contain a no-shop and if so, what section is it?\"\n",
    "    ),\n",
    "    ChatMessage(\n",
    "        role='user',\n",
    "        content=\"If the provision is included, what are the key terms and conditions of the no-shop provision?\"\n",
    "    )\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### PDF3 Use Case"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "initial_prompt3 = ChatMessage(\n",
    "    role='user',\n",
    "    content = '''\n",
    "    Please provide a detailed and thorough tabular summary of the economic \"waterfall\" provision in this LPA, integrating all defined terms and cross-referenced provisions into a single, plain english description of the economics. The audience is a sophisticated business person with a doctorate in finance.\n",
    "    '''\n",
    ")\n",
    "system_prompt3 = ChatMessage(\n",
    "    role='system',\n",
    "    content = '''\n",
    "    The audience is a sophisticated business person with a doctorate in finance.\n",
    "    The output should be tabular.\n",
    "    '''\n",
    ")\n",
    "client_prompts3 = [\n",
    "    ChatMessage(\n",
    "        role='user',\n",
    "        content = \"Provide a detailed and thorough tabular summary of the economic 'waterfall' provision in this LPA, integrating all defined terms and cross-referenced provisions into plain english description of the economics. Add the metrics of the economic 'waterfall' provisions to the table.\",\n",
    "    )\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### PDF4 Use Case"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [],
   "source": [
    "initial_prompt4 = ChatMessage(\n",
    "    role='user',\n",
    "    content = '''\n",
    "    Draft a detailed email to the general counsel of AavantiBio summarizing the main interim operating covenants that restrict AavantiBio in the period between signing and closing.\n",
    "    ''',\n",
    ")\n",
    "system_prompt4 = ChatMessage(\n",
    "    role='system',\n",
    "    content = '''\n",
    "    Draft emails in formal business language following legal standards.\n",
    "    ''',\n",
    ")\n",
    "client_prompts4 = [\n",
    "    ChatMessage(\n",
    "        role='user',\n",
    "        content = \"Draft a detailed email to the general counsel of AavantiBio summarizing the main interim operating covenants that restrict AavantiBio in the period between signing and closing.\",\n",
    "    )\n",
    "]\n",
    "\n",
    "use_cases = {\n",
    "    \"PDF1\": {'initial_prompt': initial_prompt1, 'system_prompt': system_prompt1, 'user_prompt': client_prompts1, 'docs': [pdf1_doc]},\n",
    "    \"PDF2\": {'initial_prompt': initial_prompt2, 'system_prompt': system_prompt2, 'user_prompt': client_prompts2, 'docs': [pdf2_doc]},\n",
    "    \"PDF3\": {'initial_prompt': initial_prompt3, 'system_prompt': system_prompt3, 'user_prompt': client_prompts3, 'docs': [pdf3_doc]},\n",
    "    \"PDF4\": {'initial_prompt': initial_prompt4, 'system_prompt': system_prompt4, 'user_prompt': client_prompts4, 'docs': [pdf4_doc]},\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "MODEL_LARGE = \"jamba-1.5-large\"\n",
    "MODEL_MINI = \"jamba-1.5-mini\"\n",
    "\n",
    "# run prompts as chat questions and return single response\n",
    "def run_use_case(use_case, model, client):\n",
    "    documents = use_case['docs']\n",
    "\n",
    "    messages = [\n",
    "        use_case['system_prompt']\n",
    "    ]\n",
    "\n",
    "    for q in use_case['user_prompt']:\n",
    "        messages.append(q)\n",
    "        response = client.chat.completions.create(\n",
    "            messages=messages, \n",
    "            model=model,\n",
    "            max_tokens=4096,\n",
    "            temperature=0.1,\n",
    "            documents=documents\n",
    "        )\n",
    "        response_message = response.choices[0].message\n",
    "        pprint(f\"Q: {q.content}\")\n",
    "        pprint(f\"A: {response_message.content}\")\n",
    "        messages.append(response_message)\n",
    "\n",
    "    full_question = '\\n'.join([r.content for r in messages if r.role == 'system' or r.role == 'user'])\n",
    "    full_response = '\\n'.join([r.content for r in messages if r.role == 'assistant'])\n",
    "\n",
    "    return full_question, full_response"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Document Workflow\n",
    "\n",
    "**IMPORTANT:**\n",
    "From this point the workflow is the same for all documents. Instead of code duplication for each pdf (out of 4 totals) we use variable\n",
    "```\n",
    "use_case_name = \"PDF1\"\n",
    "```\n",
    "Simply change its value to `'PDF2'`, `'PDF3'`, or `'PDF4'` to run flow for respective pdf.\n",
    "\n",
    "There are 3 ways to execute each use case:\n",
    "1. using initial prompt\n",
    "2. using enhanced (engineered) prompts - in case when they are chat-like they get concatenated into single prompt\n",
    "3. using stacking messages that simulates chat: this simulates interaction by the user asking initial prompt's questions in sequence\n",
    "\n",
    "### Initial Prompt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "**Client Alert: Key Provisions and Potential Impact of the Proposed Rule on Incentive-Based Compensation Arrangements**\n",
      "\n",
      "Dear Clients,\n",
      "\n",
      "We are pleased to share insights on the recently proposed rule regarding incentive-based compensation arrangements at financial institutions with at least $1 billion in assets. This proposal, which revives a similar initiative from 2016, includes a preamble that introduces new alternatives and questions for consideration in the final rule. Below, we provide a detailed overview of the key provisions, a summary and analysis of the preamble, and potential impacts on larger financial institutions.\n",
      "\n",
      "**Key Provisions of the Proposed Rule**\n",
      "\n",
      "The proposed rule aims to implement section 956 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. It seeks to prohibit incentive-based compensation arrangements that encourage inappropriate risks by providing excessive compensation or could lead to material financial loss. The key provisions include:\n",
      "\n",
      "1. **Prohibition on Certain Compensation Arrangements**: The rule prohibits incentive-based compensation arrangements that encourage inappropriate risks by providing excessive compensation or could lead to material financial loss.\n",
      "\n",
      "\n",
      "2. **Disclosure Requirements**: Covered institutions must disclose information concerning incentive-based compensation arrangements to the appropriate Federal regulator.\n",
      "\n",
      "\n",
      "3. **Deferral Requirements**: Certain institutions must defer a portion of incentive-based compensation for senior executive officers and significant risk-takers.\n",
      "\n",
      "\n",
      "4. **Forfeiture and Clawback Requirements**: Institutions must have mechanisms to recover incentive-based compensation if certain adverse outcomes occur.\n",
      "\n",
      "\n",
      "5. **Risk Management and Controls**: Covered institutions must have robust risk management frameworks to ensure that incentive-based compensation arrangements do not encourage inappropriate risks.\n",
      "\n",
      "\n",
      "**Summary and Analysis of the Preamble**\n",
      "\n",
      "The preamble to the proposed rule introduces several alternatives and questions for consideration in the final rule. These include:\n",
      "\n",
      "1. **Compliance Date**: The proposed rule suggests a compliance date of the first day of the first calendar quarter that begins at least 540 days after the date of publication in the Federal Register. The preamble questions whether this period is sufficient for covered institutions to implement necessary changes.\n",
      "\n",
      "\n",
      "2. **Definition of Covered Institutions**: The preamble questions whether other financial institutions should be included in the definition of \"covered institution\" and discusses the advantages and disadvantages of the current approach.\n",
      "\n",
      "\n",
      "3. **Consolidation Approach**: The preamble questions the approach to consolidation, discussing the advantages and disadvantages of treating subsidiaries of covered institutions as the same level as the parent institution.\n",
      "\n",
      "\n",
      "4. **Asset Thresholds**: The preamble questions whether the asset thresholds used in the definitions are appropriate and whether other methodologies would be more appropriate.\n",
      "\n",
      "\n",
      "5. **Significant Risk-Takers**: The preamble questions the definition of significant risk-takers, questioning whether the relative compensation test and exposure test are appropriate and whether a more flexible risk-based approach would be better.\n",
      "\n",
      "\n",
      "6. **Performance Measures**: The preamble questions whether the proposed performance measures are sufficiently tailored to balance risk and reward.\n",
      "\n",
      "\n",
      "7. **Deferral Periods**: The preamble questions whether the proposed deferral periods are appropriate and whether longer performance periods could provide similar benefits.\n",
      "\n",
      "\n",
      "8. **Options**: The preamble questions whether the limit on options should be modified and whether options should be permitted to meet the deferral requirements.\n",
      "\n",
      "\n",
      "9. **Forfeiture and Downward Adjustment**: The preamble questions whether the proposed rule should limit the discretion of covered institutions to seek to recover incentive-based compensation.\n",
      "\n",
      "\n",
      "10. **Clawback**: The preamble questions whether the clawback provisions should be modified to reduce the possibility of recovery that would duplicate recovery previously obtained under Rule 10D-1 of the SEC regulations.\n",
      "\n",
      "\n",
      "**Potential Impact on Larger Financial Institutions**\n",
      "\n",
      "The proposed rule, if implemented, could have significant implications for larger financial institutions, particularly regarding executive compensation arrangements. Here are some potential impacts:\n",
      "\n",
      "1. **Increased Compliance Burden**: Larger financial institutions may face increased compliance burdens due to the additional requirements for disclosure, recordkeeping, and governance.\n",
      "\n",
      "\n",
      "2. **Changes to Executive Compensation Structures**: The rule may necessitate changes to executive compensation structures, particularly for senior executive officers and significant risk-takers, to ensure compliance with the new requirements.\n",
      "\n",
      "\n",
      "3. **Impact on Talent Attraction and Retention**: The deferral and clawback requirements may impact the ability of larger financial institutions to attract and retain top talent, as potential employees may be deterred by the uncertainty and risk associated with these requirements.\n",
      "\n",
      "\n",
      "4. **Enhanced Risk Management Practices**: The rule may lead to enhanced risk management practices within larger financial institutions, as institutions seek to ensure that their incentive-based compensation arrangements do not encourage inappropriate risks.\n",
      "\n",
      "\n",
      "5. **Potential for Increased Costs**: The additional requirements and changes to compensation structures may result in increased costs for larger financial institutions.\n",
      "\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "The proposed rule on incentive-based compensation arrangements represents a significant development for larger financial institutions. The preamble introduces several important questions and alternatives that will be considered in the final rule, making it crucial for affected institutions to engage with the regulatory process.\n",
      "\n",
      "At our firm, we are committed to helping our clients navigate these changes and ensure compliance with the new requirements. Our team of experienced professionals is available to provide guidance and support as you adapt to these new regulations.\n",
      "\n",
      "For further information or assistance, please do not hesitate to contact us.\n",
      "\n",
      "Best regards,\n",
      "\n",
      "[Your Name]  \n",
      "M&A Partner  \n",
      "[Your Law Firm]  \n",
      "[Contact Information]\n"
     ]
    }
   ],
   "source": [
    "use_case_name = \"PDF1\"\n",
    "use_case = use_cases[use_case_name]\n",
    "response = client.chat.completions.create(\n",
    "    messages=[use_case['initial_prompt']],\n",
    "    # model=MODEL_LARGE,\n",
    "    model=MODEL_MINI,\n",
    "    max_tokens=4096,\n",
    "    temperature=0.1,\n",
    "    documents=use_case['docs']\n",
    ")\n",
    "\n",
    "print(response.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "| **Stage** | **Recipient** | **Distribution** | **Details** |\n",
    "| --- | --- | --- | --- |\n",
    "| **1. Initial Distribution** | Limited Partners | 100% of NDC | Limited Partners receive 100% of NDC until they have received an amount equal to an annual rate of 9%, compounded annually, on their aggregate unreturned Capital Contributions allocable to the Investment. |\n",
    "| **2. Subsequent Distribution** | Limited Partners | 100% of NDC | Limited Partners receive 100% of NDC pro rata until they have received an amount equal to their unreturned Capital Contributions allocated to the Investment plus their allocable share of all Management Fees and other expenses paid by the Partnership from Partnership cash flow rather than from Capital Contributions. |\n",
    "| **3. General Partner Distribution** | General Partner | 50% of NDC | 50% of NDC is allocated to the General Partner until it has received a cumulative distribution equal to 20% of all distributions made in the previous stages. |\n",
    "| **4. Final Distribution** | Limited Partners and General Partner | 80% to Limited Partners, 20% to General Partner | 80% of NDC is allocated to the Limited Partners pro rata based on their respective Percentage Interests, and 20% is allocated to the General Partner. |\n",
    "| **5. Over-Distribution** | General Partner | Return of Over-Distribution | If the General Partner has received an Over-Distribution, it must return the excess amount to the Partnership, which will then be distributed to the applicable Limited Partner(s) in accordance with Section 14.1(b). |\n",
    "| **6. Redemption of Interests** | General Partner and Affiliates | Redemption Amount | Upon removal of the General Partner, its Carried Interest and Capital Interest, and the Interests of its Affiliates, will be redeemed for an amount equal to their Fair Market Value immediately prior to removal, payable either in cash or by a promissory note. |\n",
    "| **7. Bankruptcy of General Partner** | General Partner |"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Enhanced Prompts (Concatenated)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[ChatMessage(role='system', content='\\n    Draft emails in formal business language following legal standards.\\n    '), ChatMessage(role='user', content='Draft a detailed email to the general counsel of AavantiBio summarizing the main interim operating covenants that restrict AavantiBio in the period between signing and closing.')]\n",
      "==============================================\n",
      "Subject: Summary of Interim Operating Covenants for AavantiBio\n",
      "\n",
      "Dear [General Counsel's Name],\n",
      "\n",
      "I hope this email finds you well. I am writing to provide a detailed summary of the main interim operating covenants that restrict AavantiBio during the period between signing and closing as outlined in the Agreement and Plan of Merger dated September 29, 2022.\n",
      "\n",
      "1. **Operation of Business**:\n",
      "\n",
      "\n",
      "  * AavantiBio must conduct its operations only in the ordinary course of business and in compliance with all applicable laws.\n",
      "  * The company must use commercially reasonable efforts to preserve its current business organization, physical assets, and relationships with customers, suppliers, and others.\n",
      "  * AavantiBio must continue to pay its accounts payable that are not subject to good faith dispute.\n",
      "\t\n",
      "2. **Restrictions on Issuance and Sale of Securities**:\n",
      "\n",
      "\n",
      "  * AavantiBio is prohibited from issuing or selling any stock or other securities, options, warrants, or rights to acquire such securities, except as specified in the agreement.\n",
      "  * The company cannot amend any terms of existing Company Options or restricted stock agreements.\n",
      "\t\n",
      "3. **Restrictions on Indebtedness and Investments**:\n",
      "\n",
      "\n",
      "  * AavantiBio cannot create, incur, or assume any new indebtedness, except for interest incurred on existing indebtedness and employee amounts incurred in compliance with the agreement.\n",
      "  * The company is restricted from making loans, advances, or capital contributions to, or investments in, any other person, except for investments in cash equivalents in the ordinary course of business.\n",
      "\t\n",
      "4. **Employment and Compensation**:\n",
      "\n",
      "\n",
      "  * AavantiBio cannot hire new officers or, except in the ordinary course of business, new employees or consultants.\n",
      "  * The company is restricted from increasing the compensation or fringe benefits of, or paying any bonuses to, any director, officer, employee, or consultant.\n",
      "  * AavantiBio cannot amend or accelerate the payment, right to payment, or vesting of any compensation or benefits, including any outstanding Company Equity Awards.\n",
      "\t\n",
      "5. **Acquisition and Disposal of Assets**:\n",
      "\n",
      "\n",
      "  * The company is prohibited from acquiring, selling, leasing, licensing, or disposing of any assets or property, including intellectual property, shares, or other equity interests, except in the ordinary course of business.\n",
      "  * AavantiBio cannot mortgage or pledge any property or assets or enter into any agreement that subjects any property or assets to any lien.\n",
      "\t\n",
      "6. **Amendments to Organizational Documents**:\n",
      "\n",
      "\n",
      "  * AavantiBio cannot amend its organizational documents, except as contemplated by the transactions set forth in the agreement.\n",
      "\t\n",
      "7. **Forgiveness of Loans**:\n",
      "\n",
      "\n",
      "  * The company cannot forgive any loans to any person, including its employees, officers, directors, or affiliates, except for the settlement of accounts receivable in the ordinary course of business.\n",
      "\t\n",
      "8. **Sale or License of Intellectual Property**:\n",
      "\n",
      "\n",
      "  * AavantiBio is restricted from selling, assigning, transferring, licensing, or sublicensing any Company Intellectual Property.\n",
      "\t\n",
      "9. **Change in Business or Management Structure**:\n",
      "\n",
      "\n",
      "  * The company cannot change the nature or scope of its business being carried on as of the date of the agreement or commence any new business not ancillary or incidental to its existing business.\n",
      "  * AavantiBio cannot alter its general organizational or management structure.\n",
      "\t\n",
      "10. **Tax Elections and Settlements**:\n",
      "\n",
      "\n",
      "  * The company cannot make or change any material tax election, change its annual accounting period, enter into any closing agreement, waive or extend any statute of limitations with respect to taxes, settle or compromise any tax liability, claim, or assessment, or surrender any right to claim a material refund of taxes.\n",
      "\t\n",
      "11. **Legal Proceedings**:\n",
      "\n",
      "\n",
      "  * AavantiBio cannot institute or settle any legal proceedings, except to enforce the terms of the agreement or as otherwise specified.\n",
      "\t\n",
      "12. **\n"
     ]
    }
   ],
   "source": [
    "use_case = use_cases[\"PDF4\"]\n",
    "# concatenate all prompts into a single message\n",
    "all_prompts = [use_case['system_prompt']] + use_case['user_prompt']\n",
    "docs = use_case['docs']\n",
    "user_single_prompt = ChatMessage(\n",
    "    role='user',\n",
    "    content = '\\n'.join([prompt.content for prompt in all_prompts])\n",
    ")\n",
    "\n",
    "response = client.chat.completions.create(\n",
    "    messages = [user_single_prompt],\n",
    "    model=MODEL_LARGE,\n",
    "    max_tokens=4096,\n",
    "    temperature=0.1,\n",
    "    documents=docs\n",
    ")\n",
    "print(all_prompts)\n",
    "print(\"==============================================\")\n",
    "print(response.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Use Cases via Chat with Stacked Messages (where applicable)\n",
    "\n",
    "Use function `run_use_case` to call models with each message accumulating responses (stacking) like chat messages.\n",
    "In the end all responses are concatenated into single response."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('Q: Draft a detailed email to the general counsel of AavantiBio summarizing '\n",
      " 'the main interim operating covenants that restrict AavantiBio in the period '\n",
      " 'between signing and closing.')\n",
      "('A: Subject: Summary of Interim Operating Covenants for AavantiBio\\n'\n",
      " '\\n'\n",
      " \"Dear [General Counsel's Name],\\n\"\n",
      " '\\n'\n",
      " 'I hope this email finds you well. I am writing to provide a detailed summary '\n",
      " \"of the main interim operating covenants that will restrict AavantiBio's \"\n",
      " 'operations between the signing and closing of the merger agreement with '\n",
      " 'Solid Biosciences Inc. These covenants are outlined in the Agreement and '\n",
      " 'Plan of Merger dated September 29, 2022.\\n'\n",
      " '\\n'\n",
      " '1. **Operation of Business**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * AavantiBio must conduct its operations only in the ordinary course of '\n",
      " 'business and in compliance with all applicable laws.\\n'\n",
      " '  * The company must use commercially reasonable efforts to preserve its '\n",
      " 'current business organization, physical assets, and relationships with '\n",
      " 'customers, suppliers, and others.\\n'\n",
      " '  * AavantiBio must continue to pay its accounts payable that are not '\n",
      " 'subject to good faith dispute.\\n'\n",
      " '\\t\\n'\n",
      " '2. **Issuance of Securities**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * AavantiBio is prohibited from issuing or selling any stock or other '\n",
      " 'securities, options, warrants, or rights to acquire such securities, except '\n",
      " 'as specified.\\n'\n",
      " '  * The company cannot amend any terms of existing Company Options or '\n",
      " 'restricted stock agreements.\\n'\n",
      " '\\t\\n'\n",
      " '3. **Dividends and Distributions**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * AavantiBio cannot declare, set aside, or pay any dividends or make any '\n",
      " 'other distributions in respect of its capital stock.\\n'\n",
      " '\\t\\n'\n",
      " '4. **Indebtedness and Investments**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * The company is restricted from creating, incurring, or assuming any '\n",
      " 'indebtedness, except for interest incurred on existing indebtedness and '\n",
      " 'employee amounts incurred in compliance with the agreement.\\n'\n",
      " '  * AavantiBio cannot assume, guarantee, endorse, or otherwise agree to be '\n",
      " 'liable for the obligations of any other person.\\n'\n",
      " '  * The company is restricted from making loans, advances, or capital '\n",
      " 'contributions to, or investments in, any other person, except for '\n",
      " 'investments of cash in cash equivalents in the ordinary course of business.\\n'\n",
      " '\\t\\n'\n",
      " '5. **Compensation and Benefits**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * AavantiBio cannot adopt, enter into, terminate, or amend any employment '\n",
      " 'or severance plan, agreement, or arrangement, any Company Plan, or any '\n",
      " 'collective bargaining agreement.\\n'\n",
      " '  * The company cannot increase the compensation or fringe benefits of, or '\n",
      " 'pay any bonus to, any director, officer, employee, or consultant, except as '\n",
      " 'specified.\\n'\n",
      " '  * AavantiBio cannot amend or accelerate the payment, right to payment, or '\n",
      " 'vesting of any compensation or benefits, including any outstanding Company '\n",
      " 'Equity Awards.\\n'\n",
      " '\\t\\n'\n",
      " '6. **Acquisition and Disposal of Assets**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * The company is restricted from acquiring, selling, leasing, licensing, '\n",
      " 'or disposing of any assets or property, including intellectual property or '\n",
      " 'shares in any entity, except in the ordinary course of business.\\n'\n",
      " '\\t\\n'\n",
      " '7. **Mortgages and Liens**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * AavantiBio cannot mortgage or pledge any of its property or assets or '\n",
      " 'enter into any agreement that subjects any such property or assets to any '\n",
      " 'lien, except as required by law or existing contracts.\\n'\n",
      " '\\t\\n'\n",
      " '8. **Subsidiaries and Joint Ventures**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * The company cannot form any subsidiaries or acquire any equity interest '\n",
      " 'or other interest in any other entity, except for investments of cash and '\n",
      " 'cash equivalents in the ordinary course of business.\\n'\n",
      " '  * AavantiBio cannot enter into a joint venture with any other entity.\\n'\n",
      " '\\t\\n'\n",
      " '9. **Amendments to Organizational Documents**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * The company cannot amend its organizational documents, except as '\n",
      " 'contemplated by the transactions set forth in the agreement.\\n'\n",
      " '\\t\\n'\n",
      " '10. **Loans to Persons**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * AavantiBio cannot forgive any loans to any person, including its '\n",
      " 'employees, officers, directors, or affiliates, except for the settlement of '\n",
      " 'accounts receivable in the ordinary course of business.\\n'\n",
      " '\\t\\n'\n",
      " '11. **Intellectual Property**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * The company cannot sell, assign, transfer, license, or sublicense any '\n",
      " 'Company Intellectual Property.\\n'\n",
      " '\\t\\n'\n",
      " '12. **Business Changes**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * AavantiBio cannot change the nature or scope of its business being '\n",
      " 'carried on as of the date of the agreement in any material respect or '\n",
      " 'commence any new business not ancillary or incidental to its existing '\n",
      " 'business.\\n'\n",
      " '\\t\\n'\n",
      " '13. **Accounting Methods**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * The company cannot change its accounting methods, principles, or '\n",
      " 'practices in any material respect, except as required by a generally '\n",
      " 'applicable change in GAAP or applicable law.\\n'\n",
      " '\\t\\n'\n",
      " '14. **Regulatory Filings**:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  * AavantiBio cannot make or amend any filings with the FDA, EMA, or any '\n",
      " 'other regulatory authority, except as required by applicable law.\\n'\n",
      " '\\t\\n'\n",
      " '15. **Tax Elections and Settlements**:\\n'\n",
      " '\\n')\n"
     ]
    }
   ],
   "source": [
    "use_case_name = \"PDF4\"\n",
    "use_case = use_cases[use_case_name]\n",
    "    \n",
    "full_question, full_response = run_use_case(use_case, MODEL_LARGE, client)\n",
    "\n",
    "use_cases[use_case_name].update({'full_question': full_question, 'full_response': full_response})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "    Draft emails in formal business language following legal standards.\n",
      "    \n",
      "Draft a detailed email to the general counsel of AavantiBio summarizing the main interim operating covenants that restrict AavantiBio in the period between signing and closing.\n",
      "====================================\n",
      "Subject: Summary of Interim Operating Covenants for AavantiBio\n",
      "\n",
      "Dear [General Counsel's Name],\n",
      "\n",
      "I hope this email finds you well. I am writing to provide a detailed summary of the main interim operating covenants that will restrict AavantiBio's operations between the signing and closing of the merger agreement with Solid Biosciences Inc. These covenants are outlined in the Agreement and Plan of Merger dated September 29, 2022.\n",
      "\n",
      "1. **Operation of Business**:\n",
      "\n",
      "\n",
      "  * AavantiBio must conduct its operations only in the ordinary course of business and in compliance with all applicable laws.\n",
      "  * The company must use commercially reasonable efforts to preserve its current business organization, physical assets, and relationships with customers, suppliers, and others.\n",
      "  * AavantiBio must continue to pay its accounts payable that are not subject to good faith dispute.\n",
      "\t\n",
      "2. **Issuance of Securities**:\n",
      "\n",
      "\n",
      "  * AavantiBio is prohibited from issuing or selling any stock or other securities, options, warrants, or rights to acquire such securities, except as specified.\n",
      "  * The company cannot amend any terms of existing Company Options or restricted stock agreements.\n",
      "\t\n",
      "3. **Dividends and Distributions**:\n",
      "\n",
      "\n",
      "  * AavantiBio cannot declare, set aside, or pay any dividends or make any other distributions in respect of its capital stock.\n",
      "\t\n",
      "4. **Indebtedness and Investments**:\n",
      "\n",
      "\n",
      "  * The company is restricted from creating, incurring, or assuming any indebtedness, except for interest incurred on existing indebtedness and employee amounts incurred in compliance with the agreement.\n",
      "  * AavantiBio cannot assume, guarantee, endorse, or otherwise agree to be liable for the obligations of any other person.\n",
      "  * The company is restricted from making loans, advances, or capital contributions to, or investments in, any other person, except for investments of cash in cash equivalents in the ordinary course of business.\n",
      "\t\n",
      "5. **Compensation and Benefits**:\n",
      "\n",
      "\n",
      "  * AavantiBio cannot adopt, enter into, terminate, or amend any employment or severance plan, agreement, or arrangement, any Company Plan, or any collective bargaining agreement.\n",
      "  * The company cannot increase the compensation or fringe benefits of, or pay any bonus to, any director, officer, employee, or consultant, except as specified.\n",
      "  * AavantiBio cannot amend or accelerate the payment, right to payment, or vesting of any compensation or benefits, including any outstanding Company Equity Awards.\n",
      "\t\n",
      "6. **Acquisition and Disposal of Assets**:\n",
      "\n",
      "\n",
      "  * The company is restricted from acquiring, selling, leasing, licensing, or disposing of any assets or property, including intellectual property or shares in any entity, except in the ordinary course of business.\n",
      "\t\n",
      "7. **Mortgages and Liens**:\n",
      "\n",
      "\n",
      "  * AavantiBio cannot mortgage or pledge any of its property or assets or enter into any agreement that subjects any such property or assets to any lien, except as required by law or existing contracts.\n",
      "\t\n",
      "8. **Subsidiaries and Joint Ventures**:\n",
      "\n",
      "\n",
      "  * The company cannot form any subsidiaries or acquire any equity interest or other interest in any other entity, except for investments of cash and cash equivalents in the ordinary course of business.\n",
      "  * AavantiBio cannot enter into a joint venture with any other entity.\n",
      "\t\n",
      "9. **Amendments to Organizational Documents**:\n",
      "\n",
      "\n",
      "  * The company cannot amend its organizational documents, except as contemplated by the transactions set forth in the agreement.\n",
      "\t\n",
      "10. **Loans to Persons**:\n",
      "\n",
      "\n",
      "  * AavantiBio cannot forgive any loans to any person, including its employees, officers, directors, or affiliates, except for the settlement of accounts receivable in the ordinary course of business.\n",
      "\t\n",
      "11. **Intellectual Property**:\n",
      "\n",
      "\n",
      "  * The company cannot sell, assign, transfer, license, or sublicense any Company Intellectual Property.\n",
      "\t\n",
      "12. **Business Changes**:\n",
      "\n",
      "\n",
      "  * AavantiBio cannot change the nature or scope of its business being carried on as of the date of the agreement in any material respect or commence any new business not ancillary or incidental to its existing business.\n",
      "\t\n",
      "13. **Accounting Methods**:\n",
      "\n",
      "\n",
      "  * The company cannot change its accounting methods, principles, or practices in any material respect, except as required by a generally applicable change in GAAP or applicable law.\n",
      "\t\n",
      "14. **Regulatory Filings**:\n",
      "\n",
      "\n",
      "  * AavantiBio cannot make or amend any filings with the FDA, EMA, or any other regulatory authority, except as required by applicable law.\n",
      "\t\n",
      "15. **Tax Elections and Settlements**:\n",
      "\n",
      "\n",
      "====================================\n"
     ]
    }
   ],
   "source": [
    "print(use_cases[use_case_name]['full_question'])\n",
    "print('====================================')\n",
    "print(use_cases[use_case_name]['full_response'])\n",
    "print('====================================')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "| **Metric** | **Description** | **Defined Terms and Cross-Referenced Provisions** |\n",
    "| --- | --- | --- |\n",
    "| **Net Distributable Cash** | All cash receipts from operations and capital events, reduced by principal or interest on any indebtedness, reserves, and operating expenses. | Net Distributable Cash, Operating Expenses, Capital Events |\n",
    "| **Distribution of Net Distributable Cash** | Calculated on an investment-by-investment basis and allocated among partners in proportion to their respective percentage interests. | Percentage Interest, Capital Events |\n",
    "| **Distribution to General Partner** | The full amount of Net Distributable Cash allocated to the General Partner or its affiliates is distributed to them. | General Partner, Affiliates |\n",
    "| **Distribution to Limited Partners** | Allocated in the following manner: <br> 1. 100% to the Limited Partner until it has received an amount equal to an annual rate of 9% on its aggregate unreturned capital contributions allocable to the investment. <br> 2. 100% to the Limited Partner pro rata until it has received an amount equal to its unreturned capital contributions plus its allocable share of management fees and other expenses. <br> 3. 50% to the Limited Partner and 50% to the General Partner until the General Partner has received 20% of all distributions. <br> 4. 80% to the Limited Partner and 20% to the General Partner. | Limited Partner, Capital Contributions, Management Fees, General Partner |\n",
    "| **Returned Capital** | Amount of Net Distributable Cash which represents the return of the Partnership’s invested capital in any investment that has been disposed of or refinanced. | Returned Capital, Capital Contributions |\n",
    "| **Management Fee** | Paid to the General Partner quarterly in arrears, based on each Limited Partner’s capital commitment during the investment period and each Limited Partner’s invested capital after the investment period. | Management Fee, Capital Commitment, Invested Capital |\n",
    "| **Over-Distribution** | If the General Partner has received an Over-Distribution, it shall pay the amount to the Partnership, which shall then be distributed to the applicable Limited Partner(s). | Over-Distribution, Carried Interest Distributions |\n",
    "| **Final Accounting and Clawback** | Within 120 days after the disposition of the last investment, the General Partner shall determine if there has been any Over-Distribution and shall pay the amount to the Partnership. | Final Accounting, Clawback, Over-Distribution |\n",
    "| **Cancellation of Certificate** | Upon dissolution of the Partnership and completion of winding up, the General Partner shall cause the cancellation of the Certificate and terminate the Partnership. | Cancellation of Certificate, Dissolution |\n",
    "| **Service of Process** | Each Partner consents to the service of process by mailing copies thereof, by certified mail, to such party at its address as set forth in Section 15.1. | Service of Process, Section 15.1 |\n",
    "| **Trial** | Each of the Partnership and each Partner waives their rights to a jury trial of any claim or cause of action based upon or arising out of this Agreement. | Trial, Jury Trial |\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "ai21-juniper",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
